Ivette Essers1, Sofia Ramiro2, Carmen Stolwijk3, Marc Blaauw3, Robert Landewé4, Désirée van der Heijde2, Filip van den Bosch5, Maxime Dougados6, Astrid van Tubergen3. 1. Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, and School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, the Netherlands. ivette.essers@maastrichtuniversity.nl. 2. Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, and School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, the Netherlands. 4. Department of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam; and Department of Rheumatology, Atrium Medical Center, Heerlen, the Netherlands. 5. Department of Rheumatology, Ghent University Hospital and Ghent University, Ghent, Belgium. 6. Department of Rheumatology, Paris-Descartes University, Hôpital Cochin, Assistance Publique, Hôpitaux de Paris, INSERM (U1153); Clinical Epidemiology Biostatistics, PRES Sorbonne, Paris-Cité, Paris, France.
Abstract
OBJECTIVES: To assess in patients with ankylosing spondylitis (AS) whether extra-articular manifestations (EAMs) are associated with worse functioning, worse quality of life (QoL), and more radiographic damage over time. METHODS: 12-year follow-up data from the Outcome in Ankylosing Spondylitis International Study were used, complemented with data on EAMs extracted from medical charts. Functioning was assessed by the BASFI and physical component of the SF-36, QoL by ASQoL and EuroQoL, and radiographic damage by the mSASSS. Generalised estimating equations analyses were made to assess whether EAMs were associated with these outcomes over time. RESULTS: 216 patients were included (154 (71%) men, mean age 43.6 years (SD 12.7), mean symptom duration 20.5 years (SD 11.7), and mean follow-up 8.3 years (SD 4.3). In total, 58 (26.9%) patients had acute anterior uveitis (AAU), 24 (11.1%) inflammatory bowel disease (IBD), and 14 (6.5%) psoriasis. Univariably, IBD was associated with worse BASFI over time (B=1.26, 95%-CI 0.13 to 2.39, p=0.03), but not in a multivariable model. Furthermore, in a multivariable model, IBD was associated with EuroQoL over time (B=2.93, 95%-CI 0.14 to 5.72, p=0.04). Univariably, psoriasis was associated with radiographic damage (B=-7.25, 95%-CI -14.38 to -0.12, p=0.05) and ASQoL (B= -1.94, 95%-CI -3.32 to -0.57, p<0.01) over time, but not in a multivariable model. AAU was not associated with any outcome over time. CONCLUSIONS: In this longstanding AS cohort, the presence of EAMs was not associated with functional disability, QoL or radiographic damage over time, except for IBD, which was associated with a better EuroQoL.
OBJECTIVES: To assess in patients with ankylosing spondylitis (AS) whether extra-articular manifestations (EAMs) are associated with worse functioning, worse quality of life (QoL), and more radiographic damage over time. METHODS: 12-year follow-up data from the Outcome in Ankylosing Spondylitis International Study were used, complemented with data on EAMs extracted from medical charts. Functioning was assessed by the BASFI and physical component of the SF-36, QoL by ASQoL and EuroQoL, and radiographic damage by the mSASSS. Generalised estimating equations analyses were made to assess whether EAMs were associated with these outcomes over time. RESULTS: 216 patients were included (154 (71%) men, mean age 43.6 years (SD 12.7), mean symptom duration 20.5 years (SD 11.7), and mean follow-up 8.3 years (SD 4.3). In total, 58 (26.9%) patients had acute anterior uveitis (AAU), 24 (11.1%) inflammatory bowel disease (IBD), and 14 (6.5%) psoriasis. Univariably, IBD was associated with worse BASFI over time (B=1.26, 95%-CI 0.13 to 2.39, p=0.03), but not in a multivariable model. Furthermore, in a multivariable model, IBD was associated with EuroQoL over time (B=2.93, 95%-CI 0.14 to 5.72, p=0.04). Univariably, psoriasis was associated with radiographic damage (B=-7.25, 95%-CI -14.38 to -0.12, p=0.05) and ASQoL (B= -1.94, 95%-CI -3.32 to -0.57, p<0.01) over time, but not in a multivariable model. AAU was not associated with any outcome over time. CONCLUSIONS: In this longstanding AS cohort, the presence of EAMs was not associated with functional disability, QoL or radiographic damage over time, except for IBD, which was associated with a better EuroQoL.
Authors: Bora Nam; Bon San Koo; Seoung Wan Nam; Ji-Hui Shin; Yoonah Song; Soo-Kyung Cho; Yoon-Kyoung Sung; Tae-Hwan Kim Journal: Qual Life Res Date: 2021-03-10 Impact factor: 4.147
Authors: Lucy Law; Jeanette Beckman Rehnman; Anna Deminger; Eva Klingberg; Lennart T H Jacobsson; Helena Forsblad-d'Elia Journal: Arthritis Res Ther Date: 2018-12-27 Impact factor: 5.156
Authors: Carmen Stolwijk; Ivette Essers; Filip van den Bosch; Maxime Dougados; Adrien Etcheto; Désirée van der Heijde; Robert Landewé; Anna Molto; Astrid van Tubergen; Annelies Boonen Journal: Rheumatology (Oxford) Date: 2020-07-01 Impact factor: 7.580